The CDMO model is evolving to incorporate more innovative approaches and specialist capacity as a result of the increasingly complex development pipeline. In this article, The Pharma Navigator editors provide a snapshot of some of the news from CDMOs helping innovators with their formulation requirements.

Increasingly complex and diverse molecules in the development pipeline and greater demand for patient-centricity are leading to a need for developers to employ advanced formulation approaches and strategies.

The oral dosage market is being shaped by a variety of innovations aimed at improving bioavailability, enhancing patient-centricity, and supporting complex molecules with sophisticated formulation solutions.

A new priority review program, unveiled by the FDA with the potential to dramatically reduce the regulatory review process for drug applications, will require increased agility, responsiveness, and readiness from CDMOs with less room for error.

Despite current hurdles facing biopharma and biotech companies, the recent BIO International Convention event saw innovation take center stage and provided a sentiment of optimism for the future, so long as industry does not rest on its laurels.

Drug development companies are struggling to gain financial support because management capabilities are lacking. In this BIO 2025 interview, Ali Pashazadeh from Treehill Partners discusses the investment landscape in more detail.

In this interview, Sarah Griffin from Informa Markets provides a review of CPHI Americas 2025 and teases some potential exciting innovations being planned for the 2026 edition of the conference.

While the spread of misinformation about vaccines is contributing to greater vaccine hesitancy, global rates of measles outbreaks are rising at alarming rates, leading to warnings being issued to international travelers.

As CPHI Americas wraps up for another year, we look back at some of the highlights from the conference and exhibition hall, and provide a sneak peek of a great opportunity at CPHI Frankfurt.

The change to the company’s leadership has been expedited as a result of the difficult market conditions and drop in share price that the company has experienced since mid-2024.

In this interview with The Pharma Navigator, Kevin Li from BioDuro reveals what he is looking forward to most and what the company will be showcasing at this year’s CPHI Americas event.

The Pharma Navigator sits down with Mara Candido from Aenova to learn more about the one-stop-shop experience, benefits of working with an end-to-end service provider, how advanced formulation strategies can aid with bioavailability/solubility issues, and the company’s focus for this year’s CPHI Americas event.  

As demand for biologic drug substance manufacturing rises, The Pharma Navigator, chats with Carrie Bracco from Novartis Contract Manufacturing about how this trend is impacting service providers, the challenges facing CDMOs in the space, and the benefits of strategic partnerships.

In this interview with The Pharma Navigator, Dan Dobry from Bend Bioscience chats about the value of comprehensive end-to-end services, challenges and future trends for OSD CDMOs, and the company’s focus for this year’s CPHI Americas event.

The Pharma Navigator discusses the increasingly complex therapeutic landscape and how strategic partnerships can be beneficial with Dr. Srinivasan Shanmugam from Adare, and finds out more about the company’s plans for CPHI Americas with Steven Facer, Senior Vice President, Global Sales and Marketing.

As more innovators look to develop orally administered GLP-1s further demand will be placed onto CDMOs to provide the expertise and capabilities needed to support the next generation of these drugs.

As the bio/pharma industry faces the looming threat of tariffs, it is clearer than ever that reporting on the key issues and trends set to shape industry is imperative to help stakeholders stay informed.

For decades, successful pharmaceutical manufacturing has been judged on scale. Nowadays, higher precedence is being given to speed, coping with complexity, and customization.

A challenging biotech investment landscape is shaking up the industry and having a negative impact on multiple CDMOs in the space.

Over the next five years, Novartis will be investing USD23 billion in 10 facilities, including seven new facilities.